• Delaware federal court found Liquidia’s YUTREPIA infringed two asserted claims of United Therapeutics’ U.S. Patent No. 11,826,327.
• Court upheld claims 1 and 14 as valid and infringed; other asserted claims were ruled invalid.
• Parties must submit a proposed judgment within one week, including remedies for the infringement finding.
• Potential remedies include removing the PH-ILD indication from YUTREPIA’s label or broader limits on market availability.
• Liquidia plans to appeal, citing disagreement with the ruling on the two upheld claims.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609301320PRIMZONEFULLFEED9837151) on September 30, 2026, and is solely responsible for the information contained therein.